

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-28. (cancelled)

29. (currently amended) A pharmaceutical formulation comprising a ~~the~~ lipopeptide ~~of claim 1~~, together with a pharmaceutically topical acceptable carrier, wherein,

said lipopeptide comprises a peptide antigen specific for a T cell population, said peptide antigen being coupled covalently with a lipid radical and being capable of activating the T cell population, and

said pharmaceutically topical acceptable carrier is selected from the group consisting of emulsion carriers, anhydrous liquid solvents, oils, silicones, and aqueous-based single phase liquid solvents.

30. (original) The pharmaceutical composition of claim 29, wherein the T cell population is a CD8+ T cell population, a CD4+ T cell population or a Tr1 cell population.

31. (currently amended) ~~The~~ A combined preparation comprising

- the pharmaceutical formulation of claim 29, ~~further~~
~~comprising, as a combined preparation, and~~

- the peptide antigen or a polypeptide comprising the
peptide antigen,

wherein the peptide antigen is to be administrated
~~prior to the topical administration of the lipopeptide in an~~
immunization step prior to the topical administration of the
pharmaceutical formulation of claim 29.

32. (original) The pharmaceutical composition of claim 31, wherein the prior immunization is made subcutaneously or intraperitoneally.

33-36. (cancelled)

37. (currently amended) The pharmaceutical composition of claim 29 for treating ~~or preventing~~ a mammal suffering from a disease selected from the group of skin diseases and diseases of the mucosa.

38. (currently amended) The pharmaceutical composition of claim 37, wherein,

the peptide antigen is capable of activating a Tr1 cell
population, and

the skin disease is selected from the group ~~comprising~~
consisting of psoriasis, vitiligo, prurigo, pityriasis, eruptive
cutaneous mastocystosis, scleroderma, bullous dermatitis,
cutaneous emphysema, erythema, eczema, acne, oedema, and graft
rejection ~~and melanoma~~.

39. (currently amended) The pharmaceutical composition
of claim 37, wherein,

the peptide antigen is capable of activating a Tr1 cell
population, and

the skin disease is a local inflammatory skin reaction
resulting from an outside attack ~~such as~~ selected from the group
consisting of a burn, a radiation, a cut, a sting, a graft, ~~or~~
and due to an allergen or microbe.

40. (currently amended) The pharmaceutical composition
of claim 37, wherein,

the peptide antigen is capable of activating a Tr1 cell
population, and

the disease of the mucosa is selected from the group
~~comprising~~ consisting of mucosal psoriasis, ~~candidosis,~~
autoimmune bullous dermatitis, erythema, ~~syphilis, Ducrey's~~
~~disease, melanoma and disorders such as~~ visceral ulcerations ~~and~~
~~bacterial infections~~.

41. (previously presented) The pharmaceutical composition of claim 30, wherein the Tr1 cell population is a CD3+CD4+CD18brightCD49b+ cell population.

42-43. (cancelled)

44. (currently amended) A cosmetic formulation comprising a lipopeptide or a mixture thereof, wherein said lipopeptide comprises a peptide antigen specific for a T cell population, said antigen being coupled covalently with a lipid radical and being capable of activating the T cell population, together with a cosmetically acceptable carrier selected from the group consisting of emulsion carriers, anhydrous liquid solvents, oils, silicones, and aqueous-based single phase liquid solvents, to prevent or treat disorders selected from chronic inflammatory disorders associated with ageing and its effects and autoimmune pathological disorders.

45. (new) The pharmaceutical composition of claim 37, wherein,

the peptide antigen is capable of activating a CD8+ T cell population and/or a CD4+ T cell population, and

the skin disease is melanoma.

46. (new) The pharmaceutical composition of claim 37,
wherein,

the peptide antigen is capable of activating a CD8+ T
cell population and/or a CD4+ T cell population and

the disease of the mucosa is selected from the group
consisting of candidosis, syphilis, Ducrey's disease, melanoma
and bacterial infections.